OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Appropriate methods for demonstrating biosimilar comparability support regulatory filing.
Cell and gene therapy products pose challenges for extractable and leachable studies.
Bioassay methods for cell and gene therapies require reevaluation.
October 14, 2021
SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.
AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science.
October 04, 2021
The expansion to SGS’s Poitiers facility in France is expected to improve the company’s drug development capabilities.
October 01, 2021
Establishing a data management strategy in-lab is a first step in generating successful analytical studies.
Establishing bioassay studies for biosimilar development is important for supporting regulatory filings.
September 30, 2021
In September, Codex DNA released a full-length synthetic genome for the SARS-CoV-2 delta variant, which may accelerate discovery and development of diagnostics and treatments for COVID-19.
The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.
Gyros’ new titer kit identifies adeno-associated virus serotype 9 in vector-based cell and gene therapy manufacturing.
September 29, 2021
USP is publishing the analytics-focused chapter, which considers validation activities, in advance of the official publication.
CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.